New treatment guidelines for rheumatoid arthritis introduced

Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to new guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham.

Lead author Kenneth Saag, MD, MSc, a professor in the University of Alabama Division of Clinical Immunology and Rheumatology, said the 2008 guidelines update strategies for treating RA with the goal of preventing joint damage and disability.

However, the new recommendations — which appear on the American College of Rheumatology’s Web site — do not strive to replace individualized medical decisions, he said. Instead, they are meant to guide rheumatologists, orthopedists and other health care workers toward the most updated recommendations.

The last set of American College of Rheumatology RA treatment guidelines was published in 2002.

“The recommendations developed are not intended to be used in a ‘cookbook’ or prescriptive manner, or to limit a physician’s clinical judgment,” Saag said in the press release. “They provide guidance based on clinical evidence and expert panel input.”

The recommendations focus on several classes of anti-arthritic drugs, including a potent group of agents called disease-modifying anti-rheumatic drugs (DMARDs). Newer genetically engineered DMARDs called biologics often work in combination with earlier therapies.

Many anti-arthritic drugs are designed to stop damaging inflammation, and biologics work to interrupt the chain of events that leads to inflammation.

Newer biologics called anti-TNF agents — including adalimumab (Humira), etanercept (Enbrel) and infliximab (Remicade) — prevent the production of an immunity protein that plays a role in inflammation, he said in the press release.

Some of the key recommendations include:

Methotrexate or leflunomide therapy is recommended for most patients with RA.
Anti-TNF agents etanercept, infliximab or adalimumab, along with methotrexate, can be used in new or early RA cases presenting with worsening or severe symptoms.
Doctors should not initiate or resume treatment with methotrexate, leflunomide or biologics if patients with RA have active bacterial infection, shingles (herpes-zoster), hepatitis B, hepatitis C or active or latent tuberculosis.
Doctors should not prescribe anti-TNF agents to patients with a history of heart failure, lymphoma or multiple sclerosis.

For more information:
The full list of RA treatment recommendations is available at www.rheumatology.org/publications/guidelines/index.asp?aud=mem.